RPTX — Repare Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $132.87m
- -$90.75m
- $51.13m
- 32
- 41
- 29
- 26
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 94.8 | 334 | 342 | 344 | 224 |
Net Total Receivables | 3.06 | 6.16 | 3.23 | 4.32 | 15.3 |
Prepaid Expenses | |||||
Total Current Assets | 98.6 | 347 | 351 | 354 | 244 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.42 | 8.62 | 13.1 | 9.6 | 7.54 |
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 103 | 357 | 369 | 364 | 254 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.25 | 11 | 35.1 | 78.6 | 39.1 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 12.8 | 70.3 | 80.3 | 84.6 | 41.8 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 89.9 | 287 | 288 | 280 | 212 |
Total Liabilities & Shareholders' Equity | 103 | 357 | 369 | 364 | 254 |
Total Common Shares Outstanding |